Stock Events

Stock Events

Cognetivity Neurosciences 

$0.000100
3
+$0.00+0% Thursday 20:00

Statistics

Day High
0.0019
Day Low
0.0019
52W High
0.0019
52W Low
0.0001
Volume
1,000
Avg. Volume
0
Mkt Cap
8,955.6
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

16DecExpected
Q3 2020
Q1 2021
Q2 2021
Q3 2021
Q1 2022
Q2 2022
Q3 2022
-0.08
-0.06
-0.03
-0.01
Expected EPS
N/A
Actual EPS
-0.017

Financials

-16,711.04%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
33,819.33Revenue
-5.65MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly is a major pharmaceutical company that develops drugs for neurological diseases, including Alzheimer's, which competes with CGNSF's cognitive assessment technologies.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurodegenerative diseases, including Alzheimer's disease treatments and diagnostics, directly competing with CGNSF's cognitive testing products.
Pfizer
PFE
Mkt Cap159.36B
Pfizer develops medications for various neurological conditions, which can be seen as alternatives to CGNSF's cognitive assessment tools.
Merck
MRK
Mkt Cap366B
Merck is involved in the development of treatments for Alzheimer's disease, competing in the same space as CGNSF's cognitive diagnostics.
Abbott Laboratories
ABT
Mkt Cap194.62B
Abbott Laboratories offers a range of healthcare solutions including diagnostics for neurological conditions, overlapping with CGNSF's market.
Novartis
NVS
Mkt Cap292.35B
Novartis provides healthcare solutions including neurological disease treatments, competing in the cognitive health space.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division, develops treatments for neurodegenerative diseases, competing with CGNSF's cognitive assessment tools.
AC Immune SA
ACIU
Mkt Cap263.48M
AC Immune focuses on Alzheimer's disease diagnostics and therapeutics, directly competing with CGNSF's cognitive assessment technologies.

About

Cognetivity Neurosciences Ltd. is a healthcare firm focused on advanced cognitive assessment. The company has developed a sophisticated platform for cognitive testing, designed for use across diverse settings including medical facilities, commercial environments, and by individual consumers. This innovative system's primary goal is to identify the very first signs of cognitive impairment through a comprehensive evaluation of broad brain functions, thereby assisting in the diagnosis of conditions like dementia. In addition to its core platform, Cognetivity also provides OptiMind, a dedicated wellness application. Established in 2015, the company initially operated under the name Utor Capital Corp. before officially rebranding to Cognetivity Neurosciences Ltd. in December 2017. Its main offices are situated in Vancouver, Canada.
Show more...
CEO
Sina Habibi
Employees
2500
Country
Canada
ISIN
CA19243C1005
WKN
000A2JGJZ

Listings

MU
DE
1UB.MU
OTC Link
US
CGNSF
STU
DE
1UB.STU
CN
CA
CGN.CN

0 Comments

Share your thoughts

FAQ

What is Cognetivity Neurosciences stock price today?▼
The current price of CGNSF is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Cognetivity Neurosciences stock price performance more closely on the chart.
What is Cognetivity Neurosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Cognetivity Neurosciences stocks are traded under the ticker CGNSF.
Is Cognetivity Neurosciences stock price growing?▼
CGNSF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Cognetivity Neurosciences has showed a +0% increase.
What is Cognetivity Neurosciences market cap?▼
Today Cognetivity Neurosciences has the market capitalization of 8,955.6
What were Cognetivity Neurosciences earnings last quarter?▼
CGNSF earnings for the last quarter are -0.02 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cognetivity Neurosciences revenue for the last year?▼
Cognetivity Neurosciences revenue for the last year amounts to 33,819.33 USD.
What is Cognetivity Neurosciences net income for the last year?▼
CGNSF net income for the last year is -5.65M USD.
How many employees does Cognetivity Neurosciences have?▼
As of September 05, 2026, the company has 2,500 employees.
In which sector is Cognetivity Neurosciences located?▼
Cognetivity Neurosciences operates in the Health & Wellness sector.
When did Cognetivity Neurosciences complete a stock split?▼
Cognetivity Neurosciences has not had any recent stock splits.
Where is Cognetivity Neurosciences headquartered?▼
Cognetivity Neurosciences is headquartered in Vancouver, Canada.